文章
醫療新知 > 美國專家研發程式助發現胰臟癌

美國專家研發程式助發現胰臟癌

07-09-2017

胰臟癌是死亡率最高的癌症之一,少於一成病人能活多過5年,而且病徵不明顯。美國華盛頓大學的研究人員研發了一個手機應用程式,透過分析自拍照中眼白的膽紅素水平,從而得知患胰臟癌的機率。

英國《每日郵報》報道,眼白變黃是胰臟癌的其中一個病徵,那是因為腫瘤影響體內膽紅素上升,但如果看到眼睛變黃,通常已經是癌症後期。

這個名叫BiliScreen的應用程式,能夠分析自拍者眼睛的照片,探測眼白的膽紅素水平。程式在首次的臨床測試中成功率達八成七,同時較傳統的驗血方法更方便、便宜。

程式仍需作進一步測試,希望能於九月中推出。研究人員希望能幫助不幸患上胰臟癌的人及早發現,把握時間接受治療,增加生存機會。

 

New app could use smartphone selfies to screen for pancreatic cancer

BiliScreen is a new smartphone app that can screen for pancreatic cancer by having users snap a selfie. It’s shown here with a 3-D printed box that helps control lighting conditions to detect signs of jaundice in a person’s eye.

 

BiliScreen is a new smartphone app that is designed to screen for pancreatic cancer by having users snap a selfie. It’s shown here with a 3-D printed box that helps control lighting conditions to detect signs of jaundice in a person’s eye.Dennis Wise/University of Washington

Pancreatic cancer has one of the worst prognoses — with a five-year survival rate of 9 percent — in part because there are no telltale symptoms or non-invasive screening tools to catch a tumor before it spreads.

Now, University of Washington researchers are developing an app that could allow people to easily screen for pancreatic cancer and other diseases — by snapping a smartphone selfie.

BiliScreen uses a smartphone camera, computer vision algorithms and machine learning tools to detect increased bilirubin levels in a person’s sclera, or the white part of the eye. The app is described in a paper to be presented Sept. 13 at Ubicomp 2017, the Association for Computing Machinery’s International Joint Conference on Pervasive and Ubiquitous Computing.

One of the earliest symptoms of pancreatic cancer, as well as other diseases, is jaundice, a yellow discoloration of the skin and eyes caused by a buildup of bilirubin in the blood. The ability to detect signs of jaundice when bilirubin levels are minimally elevated — but before they’re visible to the naked eye — could enable an entirely new screening program for at-risk individuals.

In an initial clinical study of 70 people, the BiliScreen app — used in conjunction with a 3-D printed box that controls the eye’s exposure to light — correctly identified cases of concern 89.7 percent of the time, compared to the blood test currently used.

“The problem with pancreatic cancer is that by the time you’re symptomatic, it’s frequently too late,” said lead author Alex Mariakakis, a doctoral student at the Paul G. Allen School of Computer Science & Engineering. “The hope is that if people can do this simple test once a month — in the privacy of their own homes — some might catch the disease early enough to undergo treatment that could save their lives.”

BiliScreen builds on earlier work from the UW’s Ubiquitous Computing Lab, which previously developed BiliCam, a smartphone app that screens for newborn jaundice by taking a picture of a baby’s skin. A recent study in the journal Pediatrics showed BiliCam provided accurate estimates of bilirubin levels in 530 infants.

In collaboration with UW Medicine doctors, the UbiComp lab specializes in using cameras, microphones and other components of common consumer devices — such as smartphones and tablets — to screen for disease.

BiliScreen provides estimates of bilirubin levels in a person’s blood. Elevated levels can be an early warning sign for pancreatic cancer, hepatitis and other diseases.

 

BiliScreen provides estimates of bilirubin levels in a person’s blood. Elevated levels can be an early warning sign for pancreatic cancer, hepatitis and other diseases.Dennis Wise/University of Washington

The blood test that doctors currently use to measure bilirubin levels — which is typically not administered to adults unless there is reason for concern — requires access to a health care professional and is inconvenient for frequent screening. BiliScreen is designed to be an easy-to-use, non-invasive tool that could help determine whether someone ought to consult a doctor for further testing. Beyond diagnosis, BiliScreen could also potentially ease the burden on patients with pancreatic cancer who require frequent bilirubin monitoring.

In adults, the whites of the eyes are more sensitive than skin to changes in bilirubin levels, which can be an early warning sign for pancreatic cancer, hepatitis or the generally harmless Gilbert’s syndrome. Unlike skin color, changes in the sclera are more consistent across all races and ethnicities.

Yet by the time people notice the yellowish discoloration in the sclera, bilirubin levels are already well past cause for concern. The UW team wondered if computer vision and machine learning tools could detect those color changes in the eye before humans can see them.

“The eyes are a really interesting gateway into the body — tears can tell you how much glucose you have, sclera can tell you how much bilirubin is in your blood,” said senior author Shwetak Patel, the Washington Research Foundation Entrepreneurship Endowed Professor in Computer Science & Engineering and Electrical Engineering.  “Our question was: Could we capture some of these changes that might lead to earlier detection with a selfie?”

BiliScreen uses a smartphone’s built-in camera and flash to collect pictures of a person’s eye as they snap a selfie. The team developed a computer vision system to automatically and effectively isolate the white parts of the eye, which is a valuable tool for medical diagnostics. The app then calculates the color information from the sclera — based on the wavelengths of light that are being reflected and absorbed — and correlates it with bilirubin levels using machine learning algorithms.

The UW team tested two different accessories for BiliScreen: a 3-D printed box to control lighting conditions and glasses that help the app calibrate colors. The goal is to remove the need for additional accessories, potentially by mining data from facial pictures.

 

The UW team tested two different accessories for BiliScreen: a 3-D printed box to control lighting conditions and glasses that help the app calibrate colors. The goal is to remove the need for additional accessories, potentially by mining data from facial pictures.Dennis Wise/University of Washington

To account for different lighting conditions, the team tested BiliScreen with two different accessories: paper glasses printed with colored squares to help calibrate color and a 3-D printed box that blocks out ambient lighting. Using the app with the box accessory — reminiscent of a Google Cardboard headset — led to slightly better results.

Next steps for the research team include testing the app on a wider range of people at risk for jaundice and underlying conditions, as well as continuing to make usability improvements — including removing the need for accessories like the box and glasses.

“This relatively small initial study shows the technology has promise,” said co-author Dr. Jim Taylor, a professor in the UW Medicine Department of Pediatrics whose father died of pancreatic cancer at age 70.

“Pancreatic cancer is a terrible disease with no effective screening right now,” Taylor said. “Our goal is to have more people who are unfortunate enough to get pancreatic cancer to be fortunate enough to catch it in time to have surgery that gives them a better chance of survival.”

Co-authors include Allen School undergraduate student Megan A. Banks, research study coordinator Lauren Phillipi and assistant professor of medicine Lei Yu.

The research was funded by the National Science Foundation, the Coulter Foundation and endowment funds from the Washington Research Foundation.

For more information, contact the research team at [email protected] or Mariakakis at [email protected].

城中活動

2022-12-15 11:00 上午 花藝班聖誕篇
2022-12-15 9:30 上午 中國傳統文化導賞團

疑難排解

會員註冊


或許你會想看
慢性淋巴細胞白血病 (CLL) 口服標靶藥 助病人長時間穩定病情
王紹明醫生 中文大學內科及藥物治療學系名譽臨床副教授 「慢性淋巴細胞白血病 (Chronic lymphocy […]
中大全球首證血糖波動不穩的肥胖型糖尿病患者有較高患癌風險 並證實接受一類常用降血壓藥物的糖尿病患者患癌風險則較低
香港中文大學(中大)醫學院利用大數據研究糖尿病患者的患癌風險,首次獲得兩項重要發現。研究團隊發現患有糖尿病並有 […]
中大葉氏家族基金腫瘤學教授陳林教授就職演講「不苦口的良藥」
抗癌治療的副作用為患者帶來巨大的生理和心理壓力,肝膽胰癌症患者更經常因器官受損,比其他癌症患者較易出現相關副作 […]
中大與國際團隊領導肺癌研究 證實Lorlatinib可成為ALK陽性晚期非小細胞肺癌一線治療
香港中文大學(中大)醫學院莫樹錦教授與國際肺癌專家團隊早前針對帶有「間變性淋巴瘤激酶(ALK)基因變異」的晚期 […]
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌 2022年8月8日 1 中大醫學院領導的一項多中心臨床研究發現 […]
新藥Dostarlimab給MMR缺損病人的新希望
新藥Dostarlimab給MMR缺損病人的新希望 [醫療新資訊] MMR缺損對人們有甚麼影響呢﹖為甚麼新藥D […]
【創新科研】中大研新型抗癌免疫療法及可彎曲手術鑽 全國挑戰杯共奪5獎
【創新科研】中大研新型抗癌免疫療法及可彎曲手術鑽 全國挑戰杯共奪5獎 ▲ 左起:病理解剖及細胞學系助理教授鄧銘 […]
芯片上的蠕蟲能視作癌症偵察器﹖
芯片上的蠕蟲能視作癌症偵察器﹖ [癌症資訊新聞] 根據《科學報告》學術期刊發表了一篇研究報告指,科學家利用秀麗 […]
基石藥業胃腸道間質瘤精準靶向藥(avapritinib)在香港正式上市 創新療法有望惠及更多患者
基石藥業胃腸道間質瘤精準靶向藥(avapritinib)在香港正式上市 創新療法有望惠及更多患者   在眾多癌 […]